Navigation Links
Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting
Date:9/2/2009

MALVERN, Penn. and WALTHAM, Mass., Sept. 2 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting. Surveyed infectious disease specialists emphasize the need for new agents that have lower relapse rates than the current standard-of-care. Currently, clinicians have limited treatment options for patients with this infection; oral metronidazole (Pfizer's Flagyl, Sanofi Aventis's Rodogyl, generics) and oral vancomycin (ViroPharma's Vancocin) are the most commonly used agents for treating both first and relapse episodes of Clostridium difficile infections in the United States and Europe.

In the new report entitled Hospital Anti-Infectives Insight Series: Clostridium Difficile, surveyed infectious disease specialists indicate that new strains of Clostridium difficile and the lack of effective second- and later-line therapies are also significant challenges in treatment.

Clostridium difficile is a gram-positive bacterium that can cause symptoms ranging from severe diarrhea to life-threatening inflammation of the colon. A new hypervirulent strain, BI/NAP1/027, has been associated with severe outbreaks of Clostridium difficile in North America and Europe, and has raised awareness about the need for improved treatment and prevention strategies for this infection.

"Clostridium difficile infections represent a growing area of concern due to the increased incidence of these infections and a limited number of treatment options," stated Lisa Arias, analyst at Decision Resources. "Surveyed physicians would like to see novel therapies that have a lower recurrence rate than current agents."

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Is Clostridium Difficile the New MRSA? Opportunities for Antibiotic Drug Development. This webinar will be held on Tuesday, September 29, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at gmorales@dresources.com.

About the Report

AMR and Decision Resources' Hospital Anti-Infectives Insight Series: Clostridium Difficile analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. This report contains both United States and European data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources; Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bipolar disorder relapses halved by Melbourne researchers
2. Lyme Disease Relapse Often a New Infection
3. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
4. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
5. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
6. Former substance abusers rarely relapse after organ transplantation
7. Omega-3 Fatty Acids Wont Prevent Crohns Relapse
8. Pill Reduces Relapses in MS Patients
9. Molecular change may reveal risk of leukemia relapse
10. What identifies cancer cells causing relapse and metastasis? Not CD133
11. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology: